BRAIN Biotech EBIT per Share
The EBIT per Share of BRAIN Biotech (BNN.DE) as of Aug 23, 2026 is -0.39 EUR. In the previous year, EBIT per Share was -0.41 EUR — a change of -3.87% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.39EUR
YoY
-3.87%
Last updated:
EBIT per Share of BRAIN Biotech is 2026 -0.39 EUR. EBIT per Share of BRAIN Biotech was 2025 -0.41 EUR. It decreases by -3.87% higher compared to the previous year.
The BRAIN Biotech EBIT per Share history
3 Years
10 Years
25 Years
Max
EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-0.30 EUR
Jan 1, 2024
-0.41 EUR
Jan 1, 2025
-0.39 EUR
Jan 1, 2026 (e)
-0.31 EUR
Jan 1, 2027 (e)
-0.34 EUR
Jan 1, 2028 (e)
-0.38 EUR
Jan 1, 2029 (e)
-0.39 EUR
Jan 1, 2030 (e)
-0.44 EUR
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | -0.44EUR | +12.36% |
| est | -0.39EUR | +2.88% |
| est | -0.38EUR | +10.36% |
| est | -0.34EUR | +11.78% |
| est | -0.31EUR | -21.14% |
| -0.39EUR | -3.87% | |
| -0.41EUR | +33.49% | |
| -0.30EUR | -11.88% | |
| -0.34EUR | +14.92% | |
| -0.30EUR | -32.90% | |
| -0.45EUR | +42.71% | |
| -0.31EUR | -43.72% | |
| -0.56EUR | +10.09% | |
| -0.51EUR | -39.22% | |
| -0.83EUR | +133.78% | |
| -0.36EUR | -8.49% | |
| -0.39EUR | — |
Access this data via the Eulerpool API
BRAIN Biotech Stock analysis
What does BRAIN Biotech do? The company BRAIN Biotechnology Research and Information Network AG is a German company specializing in biotechnology. The company was founded in 1993 and is headquartered in Zwingenberg, Germany. BRAIN has been listed on the Frankfurt Stock Exchange since 2006 and has over 500 employees worldwide.
The history of BRAIN dates back to the 1980s when the Senckenberg Institute for Biodiversity and Climate Research in Frankfurt developed a new method for isolating microorganisms. These are called extremophilic bacteria and fungi, which live in extreme environments such as hot springs or salty soils and produce special enzymes. These enzymes can be used in various applications, such as the food industry or the development of new drugs.
BRAIN has further developed this method and built an extensive portfolio of enzymes, microorganisms, and natural substances. The company is divided into three areas:
1. BioIndustrial: Enzymes and microorganisms for industrial applications are developed here, such as for the production of detergents, paper, or bioethanol.
2. BioScience: This area focuses on the research of natural substances and active ingredients from microorganisms for the pharmaceutical and cosmetics industries.
3. Consumer Products: BRAIN develops products for end consumers here, such as probiotics or enzyme preparations for digestion promotion.
BRAIN works closely with leading companies to develop innovative solutions for their needs. The company is not only focused on the development of new products but also on the optimization of existing processes. BRAIN relies on sustainable and environmentally friendly production.
An example of a product developed by BRAIN is an enzyme used in the production of fruit juice. This enzyme breaks down pectin, which is found in many types of fruit and causes the juice to become cloudy. By using this enzyme, the juice can be made clearer and more durable without the need for artificial additives. BRAIN also uses a special enzyme in the production of soy milk to improve taste and consistency.
Overall, BRAIN has filed over 600 patents and works with more than 170 customers in various industries. The company is committed to preserving biodiversity and promoting sustainability in production.
In summary, BRAIN Biotechnology Research and Information Network AG is a company specializing in the research and development of enzymes, microorganisms, and natural substances. The company has a long history and can look back on successful collaborations with leading companies in various industries. BRAIN focuses on sustainability and environmental compatibility in production and has a broad portfolio of products that can be used in various applications. BRAIN Biotech is one of the most popular companies on Eulerpool.
Frequently Asked Questions about BRAIN Biotech stock
EBIT per Share of BRAIN Biotech is -0.39 EUR in 2026.
EBIT per Share of BRAIN Biotech changed from -0.41 EUR to -0.39 EUR, representing a -3.87% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share BRAIN Biotech since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — BRAIN Biotech
All Key Metrics — BRAIN Biotech
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth